Dramatic coronary artery aneurysm regression after coronary artery bypass grafting and proprotein convertase subtilisin/kexin type 9 inhibitor therapy
{{output}}
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer clinical benefits by reducing low-density lipoprotein cholesterol levels and have emerged as valuable therapeutic agents for the management of cardiovascular diseases. Although their effect... ...
